Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Definium Therapeutics, Inc. filings document the regulatory record of a British Columbia clinical-stage biopharmaceutical company traded on Nasdaq as DFTX. Current reports on Form 8-K disclose financial results, corporate highlights, investor-presentation materials, and clinical and commercial updates for DT120 ODT in psychiatric indications.
Definitive proxy materials cover annual general and special meeting matters, including director elections, auditor appointment, compensation governance, and shareholder voting procedures. Other filings record board composition changes, non-employee director compensation, stock option awards, indemnity arrangements, and the company’s corporate identity following its former name, Mind Medicine (MindMed) Inc.
Definium Therapeutics, Inc. Chief Executive Officer Robert Barrow reported an open-market sale of 24,431 Common Shares at a weighted average price of $18.47 per share. The shares were sold to satisfy withholding tax obligations linked to vested restricted stock units under a Rule 10b5-1 sell-to-cover plan adopted on June 15, 2022.
Following this transaction, Barrow directly holds 752,454 Common Shares, and this amount includes 1,586 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan. Because the sale was for tax withholding under a pre-planned trading arrangement, it reflects a routine administrative event rather than a discretionary change in ownership.
Robert Barrow filed a Form 144 reporting an intended sale of 24,431 shares of Common stock of DFTX on 03/25/2026, described as restricted stock vesting under a registered plan. The filing also shows a prior sale of 25,791 shares on 12/26/2025.
Daniel Karlin filed a Form 144 reporting 8,018 shares of Common Stock to be sold on 03/25/2026. The filing states the shares relate to restricted stock vesting under a registered plan and lists the disposition as Issuer with reason "Services Rendered". The form also shows 5,600 shares sold on 12/26/2025 with proceeds of $73,622.00.
Mark Sullivan reports intent to sell 10,702 shares of Common Stock on 03/25/2026. The filing lists the shares as restricted stock vesting under a registered plan and identifies the transaction as involving the issuer. The filing also discloses a prior sale of 11,276 shares on 12/26/2025.
Definium Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on novel psychedelic-derived treatments for brain health disorders. Its lead candidate, DT120 ODT (lysergide D-tartrate), is in Phase 3 programs for generalized anxiety disorder (GAD) and major depressive disorder (MDD), following a Phase 2b GAD trial that met primary and key secondary endpoints and received FDA breakthrough therapy designation and a UK ILAP Innovation Passport.
The GAD Phase 3 program includes the Voyage and Panorama trials, while MDD trials include Emerge and Ascend, each with randomized, double-blind, placebo-controlled Part A phases and 40‑week open‑label extensions. A second candidate, DT402 (R(-)-MDMA), is in a Phase 2a trial for autism spectrum disorder. The company reports no approved products, ongoing net losses, the need for substantial additional capital, reliance on third-party manufacturers and CROs, and regulatory and reimbursement risks, particularly given its use of controlled substances.
Definium Therapeutics reported a larger full-year 2025 net loss of $183.8 million, compared with $108.7 million in 2024, as it ramped late-stage development for its psychedelic-based therapies.
Cash, cash equivalents and investments rose to $411.6 million as of December 31, 2025, up from $273.7 million a year earlier, helped by a $259 million equity financing completed in the fourth quarter. The company expects this cash to fund operations into 2028.
Research and development expenses increased to $117.7 million from $65.3 million, driven mainly by higher DT120 program spending and expanded R&D staffing. General and administrative costs rose to $48.6 million from $38.6 million, reflecting greater professional services, pre-commercial efforts, and personnel expenses.
Definium highlighted progress across four Phase 3 trials of DT120 ODT in major depressive disorder and generalized anxiety disorder, with its Emerge MDD study fully enrolled and multiple topline readouts anticipated in 2026. It also advanced DT402 into a Phase 2a study for autism spectrum disorder.
Definium Therapeutics, Inc. has a large shareholder group led by Commodore Capital LP reporting beneficial ownership of 7,428,775 common shares, representing 7.2% of the company as of December 31, 2025. This position includes 2,000,000 common shares plus 5,428,775 shares that can be acquired through a pre-funded warrant, which is subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 98,509,279 common shares reported outstanding as of October 31, 2025, plus the warrant shares. The filing is made jointly by Commodore Capital LP, Commodore Capital Master LP, and managing partners Robert Egen Atkinson and Michael Kramarz, who certify that the securities are not held for the purpose of changing or influencing control of the issuer. The issuer recently changed its name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc.
Driehaus Capital Management LLC, a Delaware investment adviser, reported beneficial ownership of Definium Therapeutics, Inc. common stock. Driehaus has shared voting and dispositive power over 6,537,202 shares, representing 6.64% of the company’s common stock as of the event date.
The shares are held in numerous fully discretionary client accounts managed by Driehaus, which reports potential voting and dispositive power, while clients generally do not hold more than 5% of the class individually. Driehaus states the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Definium Therapeutics.
Avoro Capital Advisors LLC and Behzad Aghazadeh have reported a new significant ownership position in Definium Therapeutics, Inc. They beneficially own 5,000,000 Common Shares, representing 5.08% of the class, with sole voting and dispositive power over these shares.
The ownership percentage is based on 98,509,279 Common Shares outstanding as of October 31, 2025, as referenced from the company’s Form 10-Q for the quarter ended September 30, 2025. The investors state that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Definium Therapeutics, Inc. received an amended Schedule 13G from Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin reporting a significant ownership position. The group reports beneficial ownership of 5,676,540 common shares, representing 5.54% of the class as of December 31, 2025.
This total includes 4,000,000 pre-funded warrants exercisable into common shares, calculated against 102,509,279 shares (98,509,279 shares outstanding as of October 31, 2025 plus the warrant shares). The warrants are subject to a 9.99% Maximum Percentage cap on post-exercise ownership, limiting how many can be exercised at any time.
The reporting persons state that the securities were not acquired to change or influence control, indicating a passive investment intent under the relevant SEC rules.